SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-14-149216
Filing Date
2014-04-18
Accepted
2014-04-18 17:20:36
Documents
4
Group Members
JOSHUA WOLFELUX CAPITAL MANAGEMENT, LLCLUX VENTURE ASSOCIATES II, LLCLUX VENTURE PARTNERS II, L.P.LUX VENTURES II PARTNERS FUND I LLCLUX VENTURES II SIDECAR, L.P.PETER HEBERTROBERT PAULL

Document Format Files

Seq Description Document Type Size
1 SC 13G d715481dsc13g.htm SC 13G 157586
2 EX-1 d715481dex991.htm EX-99.1 20271
3 EX-2 d715481dex992.htm EX-99.2 1679
4 EX-3 d715481dex993.htm EX-99.3 20208
  Complete submission text file 0001193125-14-149216.txt   201594
Mailing Address 840 MEMORIAL DRIVE 5TH FLOOR Cambridge MA 02139
Business Address 840 MEMORIAL DRIVE 5TH FLOOR Cambridge MA 02139 617-551-9600
Cerulean Pharma Inc. (Subject) CIK: 0001401914 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-88094 | Film No.: 14772499
SIC: 2834 Pharmaceutical Preparations

Mailing Address 295 MADISON AVENUE, 24TH FLOOR NEW YORK NY 10017
Business Address 295 MADISON AVENUE, 24TH FLOOR NEW YORK NY 10017 646-475-4385
Lux Ventures II, L.P. (Filed by) CIK: 0001592755 (see all company filings)

IRS No.: 000000000
Type: SC 13G